NOTIFICATION OF TRANSACTIONS OF DIRECTORS

VERNALIS PLC (the "Company")

6 May 2015

Vernalis plc (LSE: VER) announces it has, today, been informed that Nigel Sheail, Non-Executive Director, bought shares in the Company on 5 May 2015 in London.

Mr Sheail purchased a total of 84,000 ordinary shares of 1 pence each in the Company at an average purchase price of 59.9 pence per share. Mr Sheail is now the beneficial holder of 294,000 ordinary shares of 1 pence each, representing 0.066% of the Company's current issued share capital.

Enquiries:

Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development.  The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline.  Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com